By Sriparna Roy (Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs, some U.S.

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

The U.S. Food and Drug Administration has cracked down on compounded drugs, which were readily available while the patented ...

With political action underway through an executive order from President Donald Trump and pharmaceutical industry shifts emerging, the question remains whether these changes will lead to sustained ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Report from Canada’s Drug Agency says Wegovy cuts risk of heart attack, stroke or cardiovascular death by 20 per cent ...

Weight loss jabs combined with lifestyle choices can be a gamechanger for those stuck in the cycle of yo-yo-dieting.

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...